CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous Story Clarified
A previous story published on Benzinga.com (subsequently unpublished) referenced a tweet by Adam Feuerstein indicating his opinion that Alkermes' drug candidate Bydureon would be approved. Bydureon has not been approved. Neither Alkermes' CEO nor the FDA have made any statement indicating if the drug will be approved.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.